Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

BACKGROUND: The survival benefits of combining chemotherapy (at the maximum tolerated dose, MTD) with concurrent immunotherapy, collectively referred to as chemoimmunotherapy, for the treatment of squamous cell lung carcinoma (SQCLC) have been confirmed in recent clinical trials. Nevertheless, optim...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: He, Xiran, Du, Yang, Wang, Zhijie, Wang, Xin, Duan, Jianchun, Wan, Rui, Xu, Jiachen, Zhang, Pei, Wang, Di, Tian, Yanhua, Han, Jiefei, Fei, Kailun, Bai, Hua, Tian, Jie, Wang, Jie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Clinical/Translational Cancer Immunotherapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594539/
https://ncbi.nlm.nih.gov/pubmed/33115941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000807
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller